Trilogy Capital’s Biogen BIIB Stock Holding History

Trilogy Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-38	Closed	-$13K	–	179
2018 Q3	$13K	Hold	38	–	–	﹤0.01%	304
2018 Q2	$11K	Hold	38	–	–	﹤0.01%	288
2018 Q1	$10K	Buy	+38	New	+$11.8K	﹤0.01%	261

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Trilogy Capital's BIIB Position: Q4 2018 in Review

Trilogy Capital sold out of Biogen (BIIB) in Q4 2018, closing a stake of 38 shares — an estimated $13K sold.

Trilogy Capital first reported a position in BIIB in Q1 2018 and held it in 3 quarters. The position peaked at $13K in Q3 2018. 1,141 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

Trilogy Capital reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 38 Biogen shares in Q4 2018, an estimated $13K.
Trilogy Capital first reported a position in Biogen in Q1 2018 and held it in 3 quarters.
Trilogy Capital's Biogen position peaked at $13K in Q3 2018.
1,141 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.